164 related articles for article (PubMed ID: 3469195)
1. In-vitro antibacterial activity of imipenem compared with four other beta-lactam antibiotics (ceftazidime, cefotaxime, piperacillin and azlocillin) against 828 separate clinical isolates from a Portuguese hospital.
Santos-Ferreira MO; Vital JO
J Antimicrob Chemother; 1986 Dec; 18 Suppl E():23-6. PubMed ID: 3469195
[TBL] [Abstract][Full Text] [Related]
2. Antibacterial properties of imipenem with special reference to the activity against methicillin-resistant staphylococci, cefotaxime-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
Vurma-Rapp U; Kayser FH; Barberis-Maino L
J Antimicrob Chemother; 1986 Dec; 18 Suppl E():27-33. PubMed ID: 3102452
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.
Jones RN; Pfaller MA; Doern GV; Erwin ME; Hollis RJ
Diagn Microbiol Infect Dis; 1998 Mar; 30(3):215-28. PubMed ID: 9572029
[TBL] [Abstract][Full Text] [Related]
4. In-vitro activity of meropenem against clinical isolates obtained in Canada.
Clarke AM; Zemcov SJ
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():47-55. PubMed ID: 2808216
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity of biapenem, a new carbapenem antibiotic.
Clarke AM; Zemcov SJ
Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):377-84. PubMed ID: 8354306
[TBL] [Abstract][Full Text] [Related]
7. In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy.
Schito GC; Sanna A; Chezzi C; Ravizzola G; Leone F; Molinari G; Menozzi MG; Pirali F
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():57-72. PubMed ID: 2681128
[TBL] [Abstract][Full Text] [Related]
8. Comparative in-vitro activity of Sch 34343, imipenem, cefpirome and cefotaxime.
Bauernfeind A
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():155-64. PubMed ID: 3897170
[TBL] [Abstract][Full Text] [Related]
9. Antibacterial effect of imipenem in vitro against important aerobic and anaerobic strains isolated from clinical specimens.
Klietmann W; Focht J; Nösner K
Chemioterapia; 1987 Aug; 6(4):243-50. PubMed ID: 3477332
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic.
Harabe E; Kawai Y; Kanazawa K; Otsuki M; Nishino T
Drugs Exp Clin Res; 1992; 18(2):37-46. PubMed ID: 1644010
[TBL] [Abstract][Full Text] [Related]
11. In vitro antibacterial activity of imipenem against Pseudomonas and Staphylococcus species. Comparison with thirteen other antimicrobial agents.
Cristiano P; Abbate GF; Alagia I; Leonessa V; Giaquinto E; Savioli L
Drugs Exp Clin Res; 1985; 11(1):39-48. PubMed ID: 3869802
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial in vitro-activity of meropenem against 200 clinical isolates in comparison to 11 selected antibiotics.
Lang C; Beuth J; Ko HL; Tunggal L; Pulverer G
Zentralbl Bakteriol; 1992 Dec; 277(4):485-92. PubMed ID: 1303691
[TBL] [Abstract][Full Text] [Related]
13. Comparative in-vitro activity of the penem FCE 22101 against recent European blood culture isolates.
Dornbusch K; Kronvall G; Göransson E; Mörtsell E
J Antimicrob Chemother; 1989 Mar; 23 Suppl C():43-52. PubMed ID: 2732143
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin.
Braveny I; Machka K; Elsser R
Infection; 1982 Jan; 10(1):45-9. PubMed ID: 6279523
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK0787) with those of other recently developed beta-lactam derivatives.
Cullmann W; Opferkuch W; Stieglitz M; Werkmeister U
Antimicrob Agents Chemother; 1982 Aug; 22(2):302-7. PubMed ID: 6821459
[TBL] [Abstract][Full Text] [Related]
16. In-vitro comparison of ceftazidime and nine other antimicrobial agents against hospital strains of Gram-negative bacteria.
Wilkinson LD; Gentry LO
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():53-6. PubMed ID: 19802969
[TBL] [Abstract][Full Text] [Related]
17. Postantibiotic effect of imipenem on gram-positive and gram-negative micro-organisms.
Baquero F; Culebras E; Patrón C; Pérez-Díaz JC; Medrano JC; Vicente MF
J Antimicrob Chemother; 1986 Dec; 18 Suppl E():47-59. PubMed ID: 3546247
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activity of CGP 31608, a new penem antibiotic.
Eliopoulos GM; Wennersten C; Reiszner E; Moellering RC
Antimicrob Agents Chemother; 1987 Aug; 31(8):1188-93. PubMed ID: 3498437
[TBL] [Abstract][Full Text] [Related]
19. Ro 17-2301: in vitro comparison with aztreonam, imipenem, ceftazidime, cefotaxime and netilmicin.
Digranes A; Dibb WL; Benonisen E; Salveson A
Chemotherapy; 1985; 31(4):279-85. PubMed ID: 3928281
[TBL] [Abstract][Full Text] [Related]
20. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide.
Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 1997 Aug; 28(4):157-63. PubMed ID: 9327242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
